Use of eltrombopag in primary immune thrombocytopenia: report of four cases

J. Ruiz, V. Saavedra, A. Torralba
2012 European journal of hospital pharmacy. Science and practice  
Primary immune thrombocytopenia (ITP) is a disorder that is characterized by immunemediated platelet destruction and impaired platelet production. We report the cases of four patients (patients 1-4) with ITP refractory to first-line treatment (glucocorticoids and immunoglobulin) who were treated with eltrombopag to achieve platelet counts of at least 50x109/l (threshold count-TC). Data were obtained from clinical histories and laboratory data. Evaluated parameters: previous treatments, platelet
more » ... reatments, platelet counts before eltrombopag, platelet response (achievement of TC), duration of treatment to achieve TC and period of study. Results The table below shows the results of the four patients (2 men and 2 women, mean age 67 ± 19). No adverse effects were reported. All the patients are still receiving eltrombopag. CPC038 To evaluate the effectiveness of eltrombopag, the first oral thrombopoietin receptor agonist in the treatment of ITP. Purpose Background Materials and methods Platelet Our results agree with those of clinical studies that show that eltrombopag could be an effective and safe treatment for ITP patients who are refractory to other treatments. Nevertheless, further studies should be carried out to evaluate long term safety and effectiveness.
doi:10.1136/ejhpharm-2012-000074.387 fatcat:7yfww7zhn5a6lhdeb3zupmhk64